Chimerix Inc CMRX

NAS: CMRX | ISIN: US16934W1062 14/11/2024

0,900 USD (-5,26%)

(-5,26%) 14/11/2024

Grafiek Chimerix Inc

Grafiek Chimerix Inc

1 dag1d -5,26%
1 week1w -9,09%
1 maand1m 5,98%
3 maanden3m 7,77%
6 maanden6m -7,93%
1 jaar1j -6,25%
5 jaar5j -51,61%

Chimerix Inc in het nieuws

Toon enkel gratis nieuws

2 maart 2021 · Chimerix to Present at Virtual H.C. Wainwright Global Life Sciences Conference · Persbericht

26 februari 2021 · Chimerix, Exclusive Worldwide Licensee of Cantex's Investigational Product, DSTAT, Has Announced Promising Topline Results from the First Cohort of a Randomized COVID-19 Clinical Trial · Persbericht

25 januari 2021 · Chimerix Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares · Persbericht

21 januari 2021 · Chimerix Announces Pricing of Public Offering of Common Stock · Persbericht

19 januari 2021 · Chimerix Announces Proposed $75,000,000 Public Offering of Common Stock · Persbericht

8 januari 2021 · Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program · Persbericht

Profiel Chimerix Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.chimerix.com

Hoofdzetel: Durham, North Carolina Verenigde Staten

CEO: Michael Sherman

Werknemers: 103

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe